Zydus receives final approval from the USFDA for Norepinephrine Bitartrate Injection

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), has received final approval from the United States Food and Drug Administration (USFDA) to market Norepinephrine Bitartrate Injection USP,4 mg/4 mL (1 mg/mL) Single-Dose Vial. (USRLD: Levophed).

Norepinephrine Bitartrate is indicated for restoration of blood pressure in adult patients with acute hypotensive state. The drug will be manufactured at the group's topical injectable manufacturing facility at Jarod, India.

Norepinephrine Bitartrate Injection USP, 1mg/1 mL had annual sales of US$ 63.8 million in the United States according to IQVIA data (IQVIA MAT May 2022).

The group now has 317 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Ltd was last trading in BSE at Rs. 358.70 as compared to the previous close of Rs. 357.20. The total number of shares traded during the day was 39316 in over 1051 trades.

The stock hit an intraday high of Rs. 364.00 and intraday low of 358.00. The net turnover during the day was Rs. 14171902.00.

(*as of 31st March 2022)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 USFDA FinalApproval NorepinephrineBitartrate Injection